Registry update — unassessed
Exploring the Anti-ageing Effects of Metformin in COPD
Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: May 31, 2025 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The abstract reports only the study design and objectives but does not provide the actual results, effect sizes, or statistical significance, so no conclusions about metformin's efficacy can be drawn from this material
- The generalisability of any findings is limited to COPD patients with confirmed emphysema and documented rapid FEV1 decline; results would not apply to other populations
- Without reported participant numbers or completion rates, the power and reliability of any findings cannot be assessed
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 36 months
- Population
- COPD patients with evidence of emphysema (by CT scan or reduced DLCO) who are known to have a rapid decrease in FEV1
- Primary outcome
- Change in FEV1 at 3 years follow-up
- Effect size
- —
- Significance
- Not reported
- Journal
- Fundación Instituto de Investigación Sanitaria de Navarra
- Published
- May 31, 2025
Sources
Primary source
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
Prospective, multicentre, double-blind, placebo-controlled, randomised, prospective clinical trial comparing the effect of metformin 850 mg twice daily with placebo in COPD patients with evidence of emphysema (by CT scan or reduced DLCO) who are known to have a rapid decrease in FEV1.
To compare the change in FEV1 at 3 years follow-up in patients receiving metformin versus placebo.
Participants will take metformin (850mg) or placebo twice daily for 3 years.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.